Press release
Acromegaly Pipeline Insights Report 2025 by DelveInsight: Drug Development, Clinical Trial Progress, Emerging Therapies, and Strategic Company Insights
Discover the latest drugs and treatment options in the Acromegaly Pipeline. Dive into DelveInsight's comprehensive report today! @ Acromegaly Pipeline Outlook [https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Acromegaly Pipeline Report
* On 02 September 2025, Debiopharm International SA announced a study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) less than or equal to 1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
* DelveInsight's Acromegaly pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Acromegaly treatment.
* The leading Acromegaly Companies such as Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork , and others.
* Promising Acromegaly Therapies such as Paltusotine, CAM2029 (octreotide subcutaneous depot), GHR-LRX, Debio 4126, Octreotide capsules, Octreotide capsules, Lanreotide, Pasireotide LAR , and others.
Stay ahead with the most recent pipeline outlook for Acromegaly. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acromegaly Treatment Drugs [https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Acromegaly Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Acromegaly Pipeline Report also highlights the unmet needs with respect to the Acromegaly.
Acromegaly Overview
Acromegaly is a rare endocrine disorder caused by a benign tumor of pituitary gland that results in over-secretion of growth hormone (GH.) that in turn causes abnormal increase in insulin-like growth factor-1 (IGF-1). Most pituitary adenomas are slow growing and benign. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size.
Acromegaly Emerging Drugs Profile
* Paltusotine: Crinetics Pharmaceuticals Inc.
Paltusotine is a first oral, once-daily, selectively targeted somatostatin receptor type 2 (SST2) agonist developed for the treatment of acromegaly. It was designed by the Crinetics to provide a convenient once-daily option for people living with acromegaly. Paltusotine, an investigational drug for acromegaly, has received FDA acceptance of its New Drug Application (NDA). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025, for the NDA review. Currently it is in Registration stage of clinical trial evaluation to treat Acromegaly. The drug maintained the IGF-1 levels in acromegaly patients in both Phase II and in recent Phase III studies.
* Atesidorsen: Percheron Therapeutics
Atesidorsen (formerly ATL1103) is a second-generation antisense oligonucleotide developed by Percheron Therapeutics for the treatment of acromegaly, a hormonal disorder characterized by excess growth hormone and elevated IGF-1 levels. The therapy works by inhibiting the human growth hormone receptor (GHr), thereby reducing IGF-1 production. Atesidorsen showed promising results in a Phase II clinical trial, demonstrating its potential to normalize IGF-1 levels in patients. However, in April 2025, Percheron Therapeutics announced the discontinuation of atesidorsen's development, citing limited commercial viability under current development pathways. Currently the drug is in Phase II stage of its development for the treatment of Acromegaly.
* TE 8214: Immunwork
TE8214 is a nextgeneration somatostatin receptor agonist designed by Immunwork (TE Pharma Holding) for the treatment of acromegaly and neuroendocrine tumors. Its highly watersoluble, fattyacidconjugated peptide formulation enables subcutaneous administration with a fine 30gauge needle, virtually eliminating injectionsite pain and nodules seen with current therapies. In the PhaseI singleascending dose trial (completed late 2024), TE8214 was exceptionally well tolerated: in the highest dose groups, about 83% of participants achieved >20% reduction in IGF1, with minimal gastrointestinal sideeffects. Based on this strong safety and pharmacodynamic profile, Immunwork plans to initiate PhaseII trials in Taiwan in Q32025 and is actively seeking strategic partnerships to support global development. Currently the drug is in Phase I stage of its development for the treatment of Acromegaly.
Explore groundbreaking therapies and clinical trials in the Acromegaly Pipeline. Access DelveInsight's detailed report now! @ New Acromegaly Drugs [https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Acromegaly Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Acromegaly with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acromegaly Treatment.
* Acromegaly Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Acromegaly Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acromegaly market
Acromegaly Companies
Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork , and others.
Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical.
Acromegaly Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Acromegaly Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Acromegaly Market Drivers and Barriers [https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Acromegaly Pipeline Report
* Coverage- Global
* Acromegaly Companies- Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork , and others.
* Acromegaly Therapies- Paltusotine, CAM2029 (octreotide subcutaneous depot), GHR-LRX, Debio 4126, Octreotide capsules, Octreotide capsules, Lanreotide, Pasireotide LAR , and others.
* Acromegaly Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acromegaly Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Acromegaly Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Acromegaly Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Acromegaly: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Paltusotine: Crinetics Pharmaceuticals Inc.
* Product Description
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Atesidorsen: Percheron Therapeutics
* Early Stage Products (Phase I)
* Comparative Analysis
* TE 8214: Immunwork
* Inactive Products
* Acromegaly Key Companies
* Acromegaly Key Products
* Acromegaly- Unmet Needs
* Acromegaly- Market Drivers and Barriers
* Acromegaly- Future Perspectives and Conclusion
* Acromegaly Analyst Views
* Acromegaly Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acromegaly-pipeline-insights-report-2025-by-delveinsight-drug-development-clinical-trial-progress-emerging-therapies-and-strategic-company-insights]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acromegaly-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acromegaly Pipeline Insights Report 2025 by DelveInsight: Drug Development, Clinical Trial Progress, Emerging Therapies, and Strategic Company Insights here
News-ID: 4202730 • Views: …
More Releases from ABNewswire
Extensive-Stage Small Cell Lung Cancer Pipeline 2025: Innovative Clinical Develo …
DelveInsight's, "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) reaching epidemic levels worldwide and…
Glioma Market: Epidemiology, Therapies, Companies | DelveInsight | Key players i …
According to DelveInsight estimates, in 2023, the United States accounted for the highest Glioma market size, i.e. approximately USD 650 million.
Emerging therapies such as ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others are expected to drive growth in the glioma market over the coming years.
DelveInsight has released a new report titled "Glioma - Market Insights, Epidemiology, and Market Forecast 2034," providing a detailed analysis of glioma, including historical and projected…
Benign Breast Disease and Early Breast Cancer Market: Epidemiology, Therapies, C …
In the United States, Biopsy-confirmed benign breast disease diagnoses are four times more common than invasive Breast Cancers, affecting ~1 million women annually. There is lucrative potential to seize the marketplace of early-stage cancerous and benign breast disease because it is a broader indication and represents a greater population than an advanced disease.
Emerging therapies such as ECHOPULSE, ProSense, and others are expected to drive growth in the Benign Breast Disease…
HER2+ Non-Small Cell Lung Cancer Market: Epidemiology, Therapies, and Key Player …
The HER2+ NSCLC Market (Mutant, Overexpression, and Amplification) in the 7MM was USD ~850 million in 2023 and is expected to increase to USD ~3,110 million by 2034, at a CAGR of 13.2%.
Emerging therapies such as Pyrotinib, DZD9008, Mobocertinib (TAK-788), among others, are anticipated to drive significant growth in the HER2+ Non-Small Cell Lung Cancer market in the coming years.
DelveInsight has introduced a new report, "HER2+ Non-Small Cell Lung Cancer…
More Releases for Acromegaly
Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market: Key F …
The Acromegaly Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Acromegaly Market Size During the Forecast Period?
The market size for acromegaly has experienced swift expansion in the latest years. It is projected to rise from $2.15 billion in 2024 to $2.57…
Acromegaly Global Market Report 2025: Surge in Acromegaly Cases Driving Market G …
Rapid growth is expected in the Acromegaly global market, driven by rising awareness, government initiatives, and demand for effective treatments.
What Is The Projected Market Size Of The Global Acromegaly Global Market Report 2025 And Its Growth Rate?
The acromegaly market size is set for considerable growth in the coming years. Key statistics include:
• The market size grew from $2.15 billion in 2024 to an estimated $2.57 billion in 2025.
• This represents…
Exploring Acromegaly Treatment Market Growth
The global acromegaly treatment market is experiencing robust growth, with no signs of slowing down. In 2023, this market reached a significant milestone, boasting a total value of USD 1.61 billion. The future looks even more promising, with a projected compound annual growth rate (CAGR) of 7.65% from 2024 to 2032. By the end of this period, the market is expected to soar to approximately USD 3.12 billion. But what's…
Acromegaly Market - Defeating Acromegaly, Restoring Lives
Newark, New Castle, USA: The "Acromegaly Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Acromegaly Market: https://www.growthplusreports.com/report/acromegaly-market/8421
This latest report researches the industry structure, sales, revenue, price and…
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights.
The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone…
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights.
The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone…
